Quote:

---

Unfortunately, maraviroc carries a “black box” warning due to the associated serious adverse including hepatotoxicity.

Leronlimab is an inhibitor of CCR5 signaling in immune cells. Currently, more than 800 patients with HIV have received leronlimab without serious adverse events related to the agent. Given the safety profile of leronlimab, and potential adverse events with the small molecular inhibitors, we conducted studies to determine whether leronlimab could bind and block CCR5 signaling in human breast cancer cells. These studies extend prior studies by showing CCR5 inhibition both prevents metastasis and reduces the progression of established metastasis in vivo.

---